William Oh MD

William K. Oh, MD, is Director of Precision Medicine for Yale Cancer Center and Smilow Cancer Hospital, as well as The Jean and David W. Wallace Medical Director of Smilow Cancer Hospital at Greenwich Hospital. He is Professor of Internal Medicine in the Section of Medical Oncology and Hematology. At Greenwich Hospital, Dr. Oh will continue to develop integrated oncology care teams and expand the impact of multidisciplinary cancer care for patients in the region. In addition, as Director of Precision Medicine, he will focus on building a cohesive program in precision medicine, integrating basic and translational science, clinical trials, and Smilow Cancer Hospital’s Precision Medicine Tumor Board. He is committed to increasing the routine use of molecular and genetic testing for all patients with cancer, a goal he has been committed to throughout his career.

Dr. Oh is a genitourinary oncologist with decades of experience caring for patients with prostate cancer. Before his appointment at Yale, Dr. Oh served as the Chief Medical Officer and Executive Vice President of the Prostate Cancer Foundation, where he focused on barriers to the delivery of care for prostate cancer nationally. For over a decade, Dr. Oh was Chief of Hematology and Medical Oncology, Deputy Director of the NCI-designated Tisch Cancer Institute, and the Ezra Greenspan, MD Professor of Clinical Cancer Therapeutics at Icahn School of Medicine at Mount Sinai. He began his professional career at Dana-Farber Cancer Institute and Harvard Medical School, including roles as Clinical Director of the Lank Center for Genitourinary Oncology and Director of the Gelb Center for Translational Medicine.

Dr. Oh completed his undergraduate degree at Yale University, received his medical degree from New York University School of Medicine, and did his internship and residency at Brigham and Women’s Hospital before his clinical fellowship in medical oncology at Dana-Farber Cancer Institute. Dr. Oh currently serves as Chair of the American Cancer Society's National Prostate Cancer Roundtable, whose mission is to improve prostate cancer outcomes and survivorship through increasing awareness and equitable access to prevention, screening, and treatment. Also, he is the Chair of the Medical Advisory Council for the Chemotherapy Foundation, a 55-year-old organization committed to discovering novel cancer therapies.